semaglutide fatty liver disease India has approved Wegovy (semaglutide 2.4 mg) for treating MASH (metabolic dysfunction-associated steatohepatitis)—a serious form of that can silently progress to liver damage if left untreated. MASH develops when The FDA has approved Wegovy

Novo Nordisk announced FDA acceptance of their New Drug Application (NDA) for a 25 mg oral version of Wegovy for two new indications: (1) chronic weight management in adults living with obesity or who are overweight with at least one comorbid condition, and (2) to reduce the risk of major adverse cardiac events (MACE) in adults with overweight or obesity and established CVD

Many plans cover obesity medications with proper documentation of BMI and comorbidities

Agonist medications mimic natural hormones, activating the same receptors

Some folks turn to high-calorie foods or overeating to help deal with emotions like stress, boredom, anxiety, or depression

Three branded semaglutide products currently exist: Ozempic (injection, 0.25 mg to 2 mg weekly) for type 2 diabetes and cardiovascular risk reduction Wegovy (injection, up to 2.4 mg weekly) for long-term weight management in obese or overweight adults Rybelsus (oral tablet, 3 mg to 14 mg daily) for type 2 diabetes Compounded semaglutide, which some U.S